STOCK TITAN

Mereo BioPharma Group plc American Depositary Shares - MREO STOCK NEWS

Welcome to our dedicated page for Mereo BioPharma Group plc American Depositary Shares news (Ticker: MREO), a resource for investors and traders seeking the latest updates and insights on Mereo BioPharma Group plc American Depositary Shares stock.

Mereo BioPharma Group plc (NASDAQ: MREO) is a United Kingdom-based biopharmaceutical company dedicated to developing innovative therapeutics for rare and specialty diseases. The company's primary focus is on acquiring and advancing mid-stage development programs from larger pharmaceutical firms, aiming to transform patient quality of life and improve human health. Mereo's strategy includes optimizing the commercial value of its programs through strategic partnerships or, for select opportunities, by commercializing products independently.

Mereo has a robust pipeline of late-stage clinical product candidates, particularly in rare disease areas. The company's flagship candidates include setrusumab for Osteogenesis Imperfecta (OI) and alvelestat for severe Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD). Setrusumab, developed in partnership with Ultragenyx Pharmaceutical Inc., has shown promising results in reducing the annualized fracture rate by 67% in OI patients. The Phase 2/3 Orbit study continues to enroll patients, aiming for regulatory approvals from both the FDA and EMA.

Alvelestat, another key candidate, has demonstrated significant effects in clinical trials, including the ATALANTa study. The data supports its use for AATD-LD, and the company is aligning with both the FDA and EMA on Phase 3 study designs, targeting a broader patient population. Mereo is actively seeking partners for further development and commercialization of alvelestat.

Additionally, Mereo is advancing its oncology pipeline with candidates such as etigilimab (anti-TIGIT) and navicixizumab. Etigilimab is in a Phase 1b/2 trial for recurrent/advanced solid tumors, while navicixizumab has completed a Phase 1 study and is under a global licensing agreement with OncXerna Therapeutics Inc.

Financially, Mereo reported cash and short-term deposits of £51.2 million as of September 30, 2023, with a cash runway extending into 2026. The company has also recently entered into a global license agreement with ReproNovo SA for leflutrozole, a non-steroidal aromatase inhibitor.

Mereo BioPharma's commitment to rare disease therapeutics positions it as a significant player in the biopharmaceutical landscape, with ongoing advancements in its clinical programs and strategic partnerships shaping its path forward.

Rhea-AI Summary

Mereo BioPharma Group (NASDAQ: MREO), a clinical-stage biopharmaceutical company specializing in rare diseases, has announced its participation in the 2024 Cantor Global Healthcare Conference. Dr. Denise Scots-Knight, CEO of Mereo, will engage in a Fireside Chat on Wednesday, September 18, 2024, at 10:55am ET / 03:55pm BST.

Interested parties can access a live audio webcast of the event through the Investors section of Mereo's website at www.mereobiopharma.com/investors. For those unable to attend live, an archived replay of the webcast will be available on the company's website for two weeks following the event, providing an opportunity for stakeholders to stay informed about Mereo's latest developments and insights in the rare disease sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.51%
Tags
conferences
-
Rhea-AI Summary

Mereo BioPharma (NASDAQ: MREO) reported Q2 2024 financial results and provided a corporate update. Key highlights include:

- Cash position of $87.4 million as of June 30, 2024, expected to fund operations into 2027

- Phase 3 Orbit and Cosmic studies of setrusumab in OI fully enrolled

- New long-term Phase 2 data showed continued 67% reduction in fracture rates after 14 months of setrusumab treatment

- R&D expenses increased to $4.9 million, up 33% year-over-year

- Net loss of $12.3 million for Q2 2024, compared to $1.8 million in Q2 2023

The company continues to make progress on setrusumab for OI and alvelestat for AATD, with multiple potential value inflection points ahead.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Mereo BioPharma Group plc (NASDAQ: MREO), a clinical-stage biopharma firm focused on rare diseases, has announced a $50 million underwritten offering of 12,531,300 American Depositary Shares (ADS). Each ADS is priced at $3.99, representing five ordinary shares. The offering is set to close on June 17, 2024. Net proceeds will fund the setrusumab program and other corporate purposes. Investors include Frazier Life Sciences, Deerfield Management, and Perceptive Advisors, alongside existing shareholders like Rubric Capital Management and Janus Henderson Investors. Jefferies, Leerink Partners, and Cantor are managing the offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.52%
Tags
Rhea-AI Summary

Mereo BioPharma (NASDAQ: MREO), a clinical-stage biopharmaceutical company specializing in rare diseases, announced that CEO Dr. Denise Scots-Knight will participate in a Fireside Chat at the Jefferies Global Healthcare Conference. The event is scheduled for June 6, 2024, at 11:00am ET / 04:00pm BST. A live webcast will be available on Mereo's investor website, with a replay accessible for two weeks post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.9%
Tags
conferences
-
Rhea-AI Summary

Mereo BioPharma reported its Q1 2024 financial results, showing cash and cash equivalents of $48.7 million. The company expects to fund operations into 2026. Key updates include the completion of enrollment in the Orbit and Cosmic studies for setrusumab in osteogenesis imperfecta by partner Ultragenyx, and ongoing pre-launch activities in Europe. Mereo also announced progress in partnering discussions and research for alvelestat and etigilimab. Financial highlights included a 25% decrease in R&D expenses, a 8% reduction in general and administrative expenses, and a net loss of $9.0 million, compared to $12.1 million in Q1 2023. The company remains focused on advancing its clinical programs and engaging with partners for future developments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.15%
Tags
-
Rhea-AI Summary
Mereo BioPharma Group plc (MREO) announced CEO Dr. Denise Scots-Knight will participate in a Fireside Chat at the Needham Virtual Healthcare Conference. The presentation will be on April 9, 2024, at 10:15am ET / 03:15pm BST, with a live webcast accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
conferences
Rhea-AI Summary
Mereo BioPharma Group plc announced financial results for 2023, highlighting progress in Phase 2/3 Orbit and Phase 3 Cosmic studies of setrusumab in Osteogenesis Imperfecta. Partnering discussions for alvelestat are advancing, with cash of $57.4 million as of December 31, 2023, expected to fund operations until 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
-
Rhea-AI Summary
Mereo BioPharma Group plc (NASDAQ: MREO) announced that Dr. Denise Scots-Knight, CEO, will participate in a Fireside Chat at Leerink Partners Global Biopharma Conference. The live webcast can be accessed on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
conferences
-
Rhea-AI Summary
Mereo BioPharma Group plc (MREO) expects to complete enrollment in the Phase 3 portion of the Orbit Study and Phase 3 Cosmic Study for Osteogenesis Imperfecta treatment by partner Ultragenyx by 1Q 2024 and 1H 2024, respectively. The company also signed a global licensing deal for leflutrozole and reiterated its cash runway guidance into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.47%
Tags
none
Rhea-AI Summary
Mereo BioPharma Group plc provides an update on recent program developments and third quarter 2023 financial information. Setrusumab achieves a 67% reduction in annualized fracture rate in patients with osteogenesis imperfecta. Alvelestat shows significant effects on lung disease. Etigilimab shows promising efficacy in solid tumors. The Company has cash and short-term deposits of £51.2 million ($62.4 million) as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
none

FAQ

What is the current stock price of Mereo BioPharma Group plc American Depositary Shares (MREO)?

The current stock price of Mereo BioPharma Group plc American Depositary Shares (MREO) is $4.105 as of November 6, 2024.

What is the market cap of Mereo BioPharma Group plc American Depositary Shares (MREO)?

The market cap of Mereo BioPharma Group plc American Depositary Shares (MREO) is approximately 630.8M.

What is Mereo BioPharma Group plc?

Mereo BioPharma Group plc is a UK-based biopharmaceutical company focused on developing innovative therapeutics for rare and specialty diseases.

What are the main products of Mereo BioPharma?

Mereo's main products include setrusumab for treating Osteogenesis Imperfecta (OI) and alvelestat for severe Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD).

What is the focus of Mereo BioPharma's recent clinical trials?

Mereo's recent clinical trials focus on setrusumab for Osteogenesis Imperfecta and alvelestat for AATD-LD. Both have shown promising results in reducing fracture rates and lung disease progression, respectively.

Who are Mereo BioPharma's key partners?

Mereo partners with Ultragenyx Pharmaceutical Inc. for setrusumab and has a global licensing agreement with OncXerna Therapeutics Inc. for navicixizumab.

How is Mereo BioPharma financially positioned?

As of September 30, 2023, Mereo reported £51.2 million in cash and short-term deposits, with a funding runway into 2026.

What are the future plans for setrusumab?

Setrusumab is currently in a Phase 2/3 Orbit study. If successful, it could become the first FDA and EMA-approved treatment for Osteogenesis Imperfecta.

What is the latest update on alvelestat?

Alvelestat has shown significant clinical trial results for AATD-LD, and Mereo is aligning with regulatory bodies for a Phase 3 study to support full approval.

What other areas is Mereo BioPharma involved in?

In addition to rare diseases, Mereo is involved in oncology, with candidates like etigilimab for solid tumors and navicixizumab for ovarian cancer.

What are the milestone payments and royalties associated with Mereo's partnerships?

The partnership with Ultragenyx for setrusumab includes potential milestone payments up to $245 million and royalties on sales. The agreement with OncXerna for navicixizumab includes up to $300 million in milestones and royalties.

What is the significance of Mereo BioPharma's recent licensing agreement with ReproNovo SA?

Mereo has licensed leflutrozole to ReproNovo SA, receiving an upfront payment and potential future milestones up to $64.25 million, along with royalties on sales.

Mereo BioPharma Group plc American Depositary Shares

Nasdaq:MREO

MREO Rankings

MREO Stock Data

630.78M
769.26M
1.03%
65.47%
3.35%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
LONDON